TIMI Study Group
@TIMIStudyGroup
Followers
4K
Following
109
Media
179
Statuses
2K
Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.
Boston, MA
Joined September 2013
TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online. https://t.co/NXuasBCjV4
timi.org
Visit the post for more.
1
12
65
jacc.org
0
0
2
In #FOURIER, MACE risk ↑ by 11% for every +5 BMI above 30; this excess risk was substantially attenuated by the PCSK9i #evolocumab. This underscores the need to address residual CVD risk in #obesity through intensive #LDL-C ↓ and calls for condition-specific recommendations.
1
2
12
Coverage in @Healthgrades of VESALIUS-CV (TIMI 66) results and the effects of lipid lowering with #evolocumab @EBohula
https://t.co/wzI6aMoeXL
resources.healthgrades.com
New research finds that the lipid-lowering drug evolocumab may help reduce the risk of cardiovascular events when used in conjunction with statins.
0
0
2
FOURIER data on the benefit of #PCSK9i #evolocumab in adults with #T1D are now cited in the 2026 @AmDiabetesAssn Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D @YumiKangEndo @rgiugliano
https://t.co/FH0CH5KqRe
diabetesjournals.org
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to pro
0
0
2
Severe #hypertriglyceridemia patients on #Tryngolza saw far greater triglyceride drops at 6 months ➕ an 85% reduction in acute #pancreatitis risk 📉 🗨️ @marstonMD @TIMIStudyGroup shares that this may offer a way out of the pancreatitis danger zone. https://t.co/NOBQz2miOS
healio.com
Patients with severe hypertriglyceridemia treated with olezarsen vs. placebo had a significantly greater decline in triglyceride levels at 6 months as well as reduced risk for acute pancreatitis,...
0
1
1
How do Lp(a)-lowering agents affect atherogenic lipoproteins more broadly? In our @JAMACardio study, we show that olpasiran, an siRNA targeting apo(a), reduced Lp(a) in >95% without increasing non-Lp(a) particles. apoB was ultimately reduced by ~18%. @TIMIStudyGroup
1
2
5
In our new feature, "The Chairman's Corner", Dr. Marc Sabatine discusses #olezarsen results from the CORE and CORE2 trial with Dr. Nick Marston. Don't miss this exciting new video series! https://t.co/1zXQTkEXie
0
3
12
Dive into the latest in 🫀 cardiovascular research with 'From the Chairman's Corner', where Dr. Marc Sabatine discusses groundbreaking insights from the CORE and CORE2 TIMI trials and how #olezarsen is reshaping treatment for severe hypertriglyceridemia. https://t.co/1zXQTkFv7M
0
9
26
TIMI investigator @DrM_ODonoghue speaks with Dr. Ann Marie Navar about the results of #VESALIUS and #CORALreef Lipids that examine new data for both injectable and oral PCSK9i. @Medscape
https://t.co/BKRlOjCTC9
0
1
7
0
1
3
A new study shows that a triglyceride-lowering drug significantly reduced rate of acute pancreatitis in high-risk patients. Read more from @marstonMD and the @TIMIStudyGroup: https://t.co/yvVVtDqfPh
https://t.co/i8QzAIu1Im
@NEJM
0
1
3
Is CELEBRATE a game changer? See the commentary by @TIMIStudyGroup Prof. David Morrow and myself in @ESC_Journals ACVC Evaluating subcutaneous glycoprotein IIbIlla inhibition at first medical contact in STEMI - reviving an old concept with a new agent? https://t.co/MYnhwEiGYW
0
3
6
#ICYMI #OriginalResearch, DAPA ACT HF-TIMI 68 trial: in-hospital initiation of dapagliflozin did not significantly⬇️risk of CV death or worsening HF compared w/ place... https://t.co/Ygm5wdI8Eo
@SubodhVermaMD @akshaydesaimd @UoGHeartFailure @modeldoc @TIMIStudyGroup @ddbergMD
0
8
16
Coverage in @COR2EDMedEd of TIMI lipid management trials VESALIUS and CORE/CORE2 presented at #AHA25 @rgiugliano
https://t.co/A5ucY2UbPF
0
2
6
Coverage in @Medscape of FOURIER-OLE presentation at #AHA25 #evolocumab @rgiugliano
https://t.co/pgIun5bOOv
0
2
4
Coverage of TIMI #olezarsen trials CORE and CORE2 in @MassGenBrigham Newsroom @marstonMD
https://t.co/J7QaqplaDQ
0
0
2
In this first look of the AHA CS Registry, inopressors (specifically norepi) most commonly used vasoactive for CS; however, clear differences by etiology (AMI-CS vs AoC HF-CS), severity, concomitant MCS. Full manuscript now at #JAHA
https://t.co/GRSxS2KwWK
@sidpatelMD #AHA25
1
1
6
Latest #CCCTNetwork research shows overall 5% MCS device complication rate (range 2.8–10.9%). IABP (axillary ≫ femoral) and Impella CP > 5.0/5.5. Vascular (63%) ≫ Thrombotic (13%). Complications → ↑ ICU LOS & mortality. #CardioICU #Cardiogenic Shock #MCS #WaronShock #AHA25
1
3
5
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke @ebohula @marstonMD @rgiugliano
medpagetoday.com
VESALIUS-CV extends PCSK9 inhibitor's benefits to primary prevention
0
0
3
TIMI investigators @DrM_ODonoghue and @marstonMD share their insights on the latest phase 3 data for the oral PCSK9 inhibitor, enlicitide, in @JAMANetwork
jamanetwork.com
More than 4 decades ago, the advent of statins ushered in a transformative era in lipid-lowering therapy. Since then, a robust and extensive body of clinical evidence has consistently validated the...
0
1
4